Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTP4A3 | O75365 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.37 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2992292 | 1.00 | PTP4A3 (0.41) | PTP4A3NFE2L2TUBB1FDPSAR | |
| SCHEMBL20238313 | 0.83 | PTP4A3 (0.39) | PTP4A3NFE2L2TUBB1FDPSAR | |
| SCHEMBL29669048 | 0.83 | PTP4A3 (0.39) | PTP4A3NFE2L2TUBB1FDPSAR | |
| SCHEMBL20238316 | 0.83 | PTP4A3 (0.39) | PTP4A3NFE2L2TUBB1FDPSAR | |
| SCHEMBL22418044 | 0.81 | PTP4A3 (0.43) | PTP4A3NFE2L2ARTRPV4ALDH1A1 | |
| SCHEMBL3128555 | 0.78 | NFE2L2 (0.57) | NFE2L2TUBB1RELA | |
| SCHEMBL3128551 | 0.78 | NFE2L2 (0.57) | NFE2L2TUBB1RELA | |
| SCHEMBL4817679 | 0.77 | PTP4A3 (0.43) | PTP4A3NFE2L2ARTRPV4CYP11B1 | |
| SCHEMBL7454427 | 0.77 | TTR (0.54) | NFE2L2FDPSALDH1A1 | |
| SCHEMBL29010765 | 0.77 | TTR (0.54) | NFE2L2FDPSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173895-A1 | IMIDAZOLOPYRIMIDINES AND IMIDAZOLOTRIAZINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173895-A1 | IMIDAZOLOPYRIMIDINES AND IMIDAZOLOTRIAZINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) | PARP1, PARP2, PARP15 | PTP4A3 4139/4885NFE2L2 485/4885TUBB1 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.